x NoneEntity Type
0001708527
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 AZIYO BIOLOGICS, INC.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 AZIYO BIOLOGICS, INC. 
Street Address 1Street Address 2
 12510 PROSPERITY DRIVE SUITE 370
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 SILVER SPRING MARYLAND 20904 240-247-1143 



3. Related Persons
Last NameFirst NameMiddle Name
LloydRonald
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
FergusonMatthew
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
HametJeffrey
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
RakinKevin
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
ZugaW.Matthew
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
JordanMaybelle
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
Mills. Ph.D.C.Randal
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
MakesBrigidA.
Street Address 1Street Address 2
12510 Prosperity DriveSuite 370
CityState/Province/CountryZIP/Postal Code
Silver SpringMARYLAND20904
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   x Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2021-12-05 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 13999975 USD o Indefinite
Total Amount Sold $ 13999975 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 15


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aziyo Biologics Charts.
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aziyo Biologics Charts.

Aziyo Biologics, Inc. News

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Tuesday 23 April 2024 (3 days ago) • Edgar (US Regulatory)
Form DEF 14A - Other definitive proxy statements
Tuesday 23 April 2024 (3 days ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 2 April 2024 (3 weeks ago) • Edgar (US Regulatory)
Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Friday 8 September 2023 (8 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Thursday 7 September 2023 (8 months ago) • Edgar (US Regulatory)
Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices
Thursday 7 September 2023 (8 months ago) • GlobeNewswire Inc.
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
Wednesday 30 August 2023 (8 months ago) • GlobeNewswire Inc.
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 15 August 2023 (8 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 15 August 2023 (8 months ago) • Edgar (US Regulatory)
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
Tuesday 15 August 2023 (8 months ago) • GlobeNewswire Inc.
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
Tuesday 1 August 2023 (9 months ago) • GlobeNewswire Inc.
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Tuesday 18 July 2023 (9 months ago) • PR Newswire (US)

More Aziyo Biologics, Inc. News Articles